A Phase IIa Study of Recombinant Human Interleukin-22 IgG2-Fc (F 652) in Combination With Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) in Hematopoietic Stem Cell Transplantation Recipients (HSCT)

Trial Profile

A Phase IIa Study of Recombinant Human Interleukin-22 IgG2-Fc (F 652) in Combination With Systemic Corticosteroids for the Treatment of Newly Diagnosed Grade II-IV Lower Gastrointestinal Acute Graft-versus-Host Disease (aGVHD) in Hematopoietic Stem Cell Transplantation Recipients (HSCT)

Recruiting
Phase of Trial: Phase I/II

Latest Information Update: 05 May 2017

At a glance

  • Drugs F 652 (Primary) ; Prednisone
  • Indications Graft-versus-host disease
  • Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
  • Sponsors Generon (Shanghai) Corporation
  • Most Recent Events

    • 01 May 2017 Planned End Date changed from 1 Dec 2016 to 1 Jun 2018.
    • 01 May 2017 Planned primary completion date changed from 1 Dec 2016 to 1 Dec 2017.
    • 01 May 2017 Status changed from not yet recruiting to recruiting.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top